{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:35:49Z","timestamp":1780922149744,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.abd.2021.05.016","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T12:38:08Z","timestamp":1647607088000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunobiologicals in dermatology"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-9330","authenticated-orcid":false,"given":"Dimitri Luz Felipe da","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9036-4200","authenticated-orcid":false,"given":"Elisa Nunes","family":"Secamilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-121X","authenticated-orcid":false,"given":"Mariana Valbon","family":"Beleli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-2385","authenticated-orcid":false,"given":"Juliana Yumi","family":"Massuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1657-4570","authenticated-orcid":false,"given":"Andrea F.E.C.","family":"Franca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-932X","authenticated-orcid":false,"given":"Renata F.","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2021.05.016_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2302\/kjm.60.37","article-title":"Therapeutic monoclonal antibodies","volume":"60","author":"Yamada","year":"2011","journal-title":"Keio J Med"},{"key":"10.1016\/j.abd.2021.05.016_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/clpt.2009.294","article-title":"How innovative technology is moving biologics into the 21st century","volume":"87","author":"Robinson","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.abd.2021.05.016_bib0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.12659\/MSM.890331","article-title":"A guide to prepare patients with inflammatory bowel diseases for anti-TNF-\u03b1 therapy","volume":"20","author":"Chebli","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.abd.2021.05.016_bib0020","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1067\/mjd.2001.112353","article-title":"Treatment of psoriatic arthritis with etanercept","volume":"44","author":"Kurschat","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0025","first-page":"139","article-title":"Remicade\u00ae (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.abd.2021.05.016_bib0030","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in moderate to severe psoriasis patients: double-blind, randomized clinical trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0035","first-page":"55","article-title":"Efficacy and safety results from the comparative study of adalimumab (Humira) versus methotrexate versus placebo in psoriasis patients (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0045","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.2310\/7750.2009.00022","article-title":"Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies","volume":"13","author":"Papp","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2021.05.016_bib0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a retreatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","volume":"162","author":"Lebwohl","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0091270009343695","article-title":"Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis","volume":"50","author":"Zhouh","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.abd.2021.05.016_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000990","article-title":"Efficacy of ustekinumab in biologic-na\u00efve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2","volume":"5","author":"McInnes","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.abd.2021.05.016_bib0070","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14712598.2019.1555235","article-title":"Anti-IL17 therapies for psoriasis","volume":"19","author":"Silfvast-Kaiser","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.abd.2021.05.016_bib0080","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T-cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.abd.2021.05.016_bib0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2021.05.016_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000478072","article-title":"Adverse Reactions to Biologics in Psoriasis","volume":"53","author":"Lockwood","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0095","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2021.05.016_bib0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ad.2016.09.021","article-title":"Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis","volume":"108","author":"Azevedo","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2021.05.016_bib0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/1744666X.2015.1023295","article-title":"Ixekizumab for treatment of psoriasis","volume":"11","author":"Dyring-Andersen","year":"2015","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.abd.2021.05.016_bib0115","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2021.05.016_bib0120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2340\/00015555-3245","article-title":"Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes","volume":"99","author":"Puig","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2021.05.016_bib0125","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2021.05.016_bib0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.abd.2021.05.016_bib0135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2021.05.016_bib0140","first-page":"826","article-title":"Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years","volume":"17","author":"Griffiths","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0145","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2021.05.016_bib0155","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2021.05.016_bib0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.abd.2021.05.016_bib0165","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2021.05.016_bib0170","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2021.05.016_bib0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.abd.2021.05.016_bib0180","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2018.04.013","article-title":"Chronic Spontaneous Urticaria: The Devil\u2019s Itch","volume":"6","author":"Saini","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.abd.2021.05.016_bib0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2021.05.016_bib0190","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2021.05.016_bib0195","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2021.05.016_bib0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1590\/abd1806-4841.2019940206","article-title":"Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus \u2013 Brazilian Society of Dermatology","volume":"94","author":"Porro","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2021.05.016_bib0205","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.abd.2021.05.016_bib0210","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059622000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059622000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:41:12Z","timestamp":1759794072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059622000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0365059622000320"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2021.05.016","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunobiologicals in dermatology","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2021.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}